|Systematic (IUPAC) name|
|Legal status||Prescription Only (S4) (AU) POM (UK)|
|Routes||Oral, IM, IV|
|Metabolism||The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours.|
|Half-life||Half-Life (1.4–4 hours).|
|Excretion||The drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine.|
|Mol. mass||233.34922 g/mol|
|(what is this?)|
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s. Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth). A partial µ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full µ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.
It does not appear in the US Controlled Substances Act 1970; it may or may not be regulated as an analogue of controlled relatives such as proheptazine (ACSCN 9643)
- US patent 4197239, Cavalla JF, Shepherd RG, White AC, "Hexahydroazepine, Piperidine and Pyrrolidine Derivatives", issued 1980-04-08, assigned to Wyeth
- Holmes B, Ward A (1985). "Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy". Drugs 30 (4): 285–312. doi:10.2165/00003495-198530040-00001. PMID 2998723.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|